Cargando…

Renal function evaluation in patients with American Cutaneous Leishmaniasis after specific treatment with pentavalent antimonial

BACKGROUND: Renal evaluation studies are rare in American Cutaneous Leishmaniasis (ACL). The aim of this study is to investigate whether specific treatment reverts ACL-associated renal dysfunction. METHODS: A prospective study was conducted with 37 patients with ACL. Urinary concentrating and acidif...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oliveira, Rodrigo A, Lima, Cláudio G, Mota, Rosa Ms, Martins, Alice Mc, Sanches, Talita R, Seguro, Antônio C, Andrade, Lúcia C, Junior, Geraldo B Silva, Libório, Alexandre B, Daher, Elizabeth F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3444398/ https://www.ncbi.nlm.nih.gov/pubmed/22715954 http://dx.doi.org/10.1186/1471-2369-13-44

Ejemplares similares

New World Cutaneous Leishmaniasis Treated with Intralesional Injection of Pentavalent Antimony
por: Shin, Ji Yeon, et al.
Publicado: (2013)

Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review
por: Brito, Nayara Castelano, et al.
Publicado: (2017)

A retrospective cohort study of the effectiveness and adverse events of intralesional pentavalent antimonials in the treatment of cutaneous leishmaniasis
por: Rodrigues, Bruna Côrtes, et al.
Publicado: (2020)

Pentavalent Antimonials Combined with Other Therapeutic Alternatives for the Treatment of Cutaneous and Mucocutaneous Leishmaniasis: A Systematic Review
por: Berbert, Taisa Rocha Navasconi, et al.
Publicado: (2018)

American tegumentary leishmaniasis: severe side effects of pentavalent antimonial in a patient with chronic renal failure
por: Marques, Sílvio Alencar, et al.
Publicado: (2019)

A Pilot Randomized Clinical Trial: Oral Miltefosine and Pentavalent Antimonials Associated With Pentoxifylline for the Treatment of American Tegumentary Leishmaniasis
por: Martins, Sofia Sales, et al.
Publicado: (2021)

Assessment of Immune and Clinical Response in Patients with Mucosal Leishmaniasis Treated with Pentavalent Antimony and Pentoxifylline
por: Cincura, Carolina, et al.
Publicado: (2022)

First-Line Therapy for Human Cutaneous Leishmaniasis in Peru Using the TLR7 Agonist Imiquimod in Combination with Pentavalent Antimony
por: Miranda-Verastegui, Cesar, et al.
Publicado: (2009)

The Pentavalent Antimony Compounds in Tropical Medicine
por: Schmidt, Hans
Publicado: (1928)

In Vitro Reduced Susceptibility to Pentavalent Antimonials of a Leishmania infantum Isolate from a Human Cutaneous Leishmaniasis Case in Central Italy
por: Diotallevi, Aurora, et al.
Publicado: (2021)

Pentavalent Antimonials: New Perspectives for Old Drugs
por: Frézard, Frédéric, et al.
Publicado: (2009)

The Extraordinary Case of a Woman with a 30-Year-Long Diffuse Leishmaniasis Cured with One Single Ampoule of Intranasal Pentavalent Antimoniate
por: Gonçalves, Sheila V. C. B., et al.
Publicado: (2023)

Mixed Antimony(V) Complexes with Different Sugars to Modulate the Oral Bioavailability of Pentavalent Antimonial Drugs
por: Ferreira, Weverson A., et al.
Publicado: (2014)

Ramsey hunt syndrome after antimonial treatment for American Cutaneous Leishmaniasis
por: Cavalcante, Melissa de Sousa Melo, et al.
Publicado: (2020)

Risk factors for antimony treatment failure in American Cutaneous Leishmaniasis in Northwestern-Argentina
por: García-Bustos, María F., et al.
Publicado: (2021)

CpG ODN D35 improves the response to abbreviated low-dose pentavalent antimonial treatment in non-human primate model of cutaneous leishmaniasis
por: Thacker, Seth G, et al.
Publicado: (2020)

“Cheaper and better”: Societal cost savings and budget impact of changing from systemic to intralesional pentavalent antimonials as the first-line treatment for cutaneous leishmaniasis in Bolivia
por: Eid Rodríguez, Daniel, et al.
Publicado: (2019)

Pharmacometabolomics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis
por: Vargas, Deninson Alejandro, et al.
Publicado: (2019)

Clinical and Parasitological Features of Patients with American Cutaneous Leishmaniasis that Did Not Respond to Treatment with Meglumine Antimoniate
por: Perez-Franco, Jairo E., et al.
Publicado: (2016)

Urban American cutaneous leishmaniasis
por: Carneiro, Francisca Regina Oliveira, et al.
Publicado: (2018)

Reactions Following the Administration of the Pentavalent Compounds of Antimony: An Analysis of Cases Reported by Several Correspondents
por: Napier, L. Everard
Publicado: (1926)

American cutaneous leishmaniasis in French Guiana: a retrospective comparison between liposomal amphotericin B and meglumine antimoniate
por: Senchyna, A., et al.
Publicado: (2020)

Occupationally Acquired American Cutaneous Leishmaniasis
por: Felinto de Brito, Maria Edileuza, et al.
Publicado: (2012)

Comparison of Oral Zinc Sulfate with Systemic Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis
por: Yazdanpanah, Mohamad Javad, et al.
Publicado: (2011)

RESOLUTION OF CUTANEOUS LEISHMANIASIS AFTER ACUTE ECZEMA DUE TO INTRALESIONAL MEGLUMINE ANTIMONIATE
por: Vasconcellos, Erica de Camargo Ferreira e, et al.
Publicado: (2014)

Immuno-pharmacokinetics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis Caused by Leishmania (Viannia)
por: Gómez, María Adelaida, et al.
Publicado: (2020)

Intralesional Meglumine Antimoniate: Safe, Feasible and Effective Therapy for Cutaneous Leishmaniasis in Bolivia
por: Rojas Cabrera, Ernesto, et al.
Publicado: (2022)

In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate
por: Carrió, Jaume, et al.
Publicado: (2002)

Towards a standard protocol for antimony intralesional infiltration technique for cutaneous leishmaniasis treatment
por: da Silva, Rosiana Estéfane, et al.
Publicado: (2018)

The effect of Nd:YAG laser therapy on cutaneous leishmaniasis compared to intralesional meglumine antimoniate
por: Omidian, Mohammad, et al.
Publicado: (2019)

Recurrent American Cutaneous Leishmaniasis
por: Gangneux, Jean-Pierre, et al.
Publicado: (2007)

American cutaneous leishmaniasis in Brazil
por: Wiwanitkit, Viroj
Publicado: (2015)

FACTORS ASSOCIATED TO ADHERENCE TO DIFFERENT TREATMENT SCHEMES WITH MEGLUMINE ANTIMONIATE IN A CLINICAL TRIAL FOR CUTANEOUS LEISHMANIASIS
por: Ribeiro, Madelon Novato, et al.
Publicado: (2014)

PANCREATIC TOXICITY AS AN ADVERSE EFFECT INDUCED BY MEGLUMINE ANTIMONIATE THERAPY IN A CLINICAL TRIAL FOR CUTANEOUS LEISHMANIASIS
por: LYRA, Marcelo Rosandiski, et al.
Publicado: (2016)

Alterations in Evoked Otoacoustic Emissions by the Use of Meglumine Antimoniate in American Tegumentary Leishmaniasis Patients
por: de Oliveira Bezerra, Débora Cristina, et al.
Publicado: (2017)

Low versus high dose of antimony for American cutaneous leishmaniasis: A randomized controlled blind non-inferiority trial in Rio de Janeiro, Brazil
por: Saheki, Mauricio Naoto, et al.
Publicado: (2017)

The Immunology of a Healing Response in Cutaneous Leishmaniasis Treated with Localized Heat or Systemic Antimonial Therapy
por: Lakhal-Naouar, Ines, et al.
Publicado: (2015)

Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis
por: Berger, Brandon A., et al.
Publicado: (2017)

The effect of oral miltefosine in treatment of antimoniate resistant anthroponotic cutaneous leishmaniasis: An uncontrolled clinical trial
por: Tayyebi, Masoumeh, et al.
Publicado: (2021)

Leprosy and American cutaneous leishmaniasis coinfection
por: Mercadante, Larissa Mondadori, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_upmp1suo00b5ld37mj8v9uu92a